Online inquiry

IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8962MR)

This product GTTS-WQ8962MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL1RL2 gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_001351446.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8808
UniProt ID Q9HB29
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8962MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14598MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ1760MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ150MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ3165MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ9923MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ13618MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ3668MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ12121MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW